Aging Kairos: treating older Hodgkin patients

Daniel Molin
DOI: https://doi.org/10.1182/blood.2023023125
IF: 20.3
2024-03-15
Blood
Abstract:In this issue of Blood , Ghesquières et al 1 conclude that the prednisone, vinblastine, doxorubicin, and bendamustine (PVAB) regimen, which lacks any novel drugs, could be a valuable nonbleomycin regimen for older patients with classical Hodgkin lymphoma (cHL). They also note that the outcome of older patients with chemotherapy-treated cHL remains dismal, regardless of the chemotherapy regimen used, and needs improvement.
hematology
What problem does this paper attempt to address?